Why are Medicare and Medicaid shown separately instead of combined?

They come from two different CMS data sources with no shared claim identifier, so they can't be reconciled into one number without double-counting or guessing. Every table and chart on this page keeps them fully separate.

Why is there no private/commercial revenue figure?

Private and commercial payer data comes from Transparency in Coverage files, which only publish negotiated rates — not claims or utilization volume. Without a volume figure, no revenue number can be computed for any provider from that data.

What does "Rank" mean in the Competitive Analysis & Benchmarks tables?

For a given CPT/HCPCS code, it's this provider's position by claims volume among all providers billing that same code at that geography level (State, National, or Florida for Medicaid) — rank 1 means the highest claims volume for that code.

Why is the Medicaid comparison limited to Florida only?

Medicaid is administered per-state with no single national fee schedule, so a state or national comparison the way Medicare has one isn't available. Florida (this provider's own state) is the only grouping that's conceptually meaningful.

Why are the numbers rounded to the nearest 10?

To avoid implying more precision than the underlying data supports at a single-provider level. Ratios are kept precise since they're a relative comparison, not a volume or dollar figure.

How current is this data?

The Medicare and Medicaid tables are both single current snapshots, not refreshed on a recurring schedule yet.

Vijay Patel (NPI 1326260837)

Field	Value
Entity Type	Individual
Organization	Vijay Patel
Address	6420 W Newberry Rd
City	Gainesville
State	FL
ZIP	32605
Taxonomy	Medical Oncology Physician
NPI Enumerated	May 3, 2007

Payer Source	Total Paid
Medicare	$4.8M
Medicaid	$0

Key Findings

VIJAY PATEL is a Medical Oncology Physician based in GAINESVILLE, FL with an NPI enumerated on 2007-05-03 (~19 years ago). The provider’s Medicare lifetime revenue is $4.8M and there is no Medicaid billing on file, indicating long tenure and a practice footprint that, in the available data, is effectively single-payer (Medicare) in scale.

Revenue concentration is highly focused: the precomputed top 3 Medicare codes account for 73.0% of this provider’s total Medicare revenue. Those top contributors are J9271 ($1.6M, 33.7%), J9299 ($1.2M, 26.8%), and J0897 ($575.6K, 12.5%), which together dominate the payer mix for Medicare.

The top codes (J9271, J9299, J0897) are systemic oncology biologics and bone-modifying agents (pembrolizumab, nivolumab, denosumab) and their dominance—both by revenue share and absolute dollars—signals an operation centered on high-volume infusion and biologic therapy delivery rather than primarily office-based procedures. Average paid/claim figures for these drugs (J9271 $43 avg paid/claim; J9299 $24 avg paid/claim; J0897 $18 avg paid/claim) further reflect a large number of low-unit payments consistent with per-mg oncology billing.

On national competitive standing, this provider is a major outlier for several of the highest-revenue drugs: J9299 ranks #10 of 505 providers nationally (98th percentile; notably above typical national volume) and J0897 ranks #83 of 10057 providers nationally (99th percentile; extreme outlier, far above typical national volume). J9271 also ranks well above peers at #51 of 1841 (97th percentile; notably above typical national volume), indicating the provider is a high-volume national participant for key immunotherapy and supportive oncology agents.

Beyond drug revenue, the practice shows outsized ambulatory E/M and infusion throughput consistent with longitudinal oncology care. 99214 appears as 1.4K claims and $138.7K revenue and ranks #4040 of 479517 providers nationally (99th percentile; extreme outlier), while 99205 has 149 claims and $24.7K revenue and ranks #1003 of 66257 providers nationally (98th percentile; extreme outlier), supporting a mix of both complex new-patient evaluations and frequent established-patient management.

Chemotherapy administration and infusion codes reinforce high infusion clinic activity: 96413 (907 claims, $88K, ranks #115 of 7514, 98th percentile; extreme outlier), 96365 (653 claims, $30.7K, ranks #227 of 8873, 97th percentile; notably above typical national volume), and the add-on 96417 (318 claims, $15.6K, ranks #45 of 3014, 99th percentile; notably above typical national volume) all sit well above typical national volumes, indicating sustained infusion/chemotherapy throughput.

The absence of any Medicaid billing on file (listed as "none below") means this provider’s publicly visible reimbursement exposure is concentrated in Medicare and commercial payers rather than Medicaid; for payers and network analysts this suggests limited Medicaid contracting footprint or patient mix that yields minimal Medicaid claims. Given the concentration in a few high-volume drug codes, payers should view total exposure as concentrated in immunotherapy and supportive biologic utilization rather than broad multispecialty service lines.

For payers and competitors assessing market positioning, the mix of very high national ranks for key oncology drugs combined with extreme outlier status on E/M and chemotherapy administration codes portrays a focused, high-throughput oncology infusion practice with substantial Medicare revenue at stake. Contracting, utilization management, and network decisions should account for the provider’s outsized role in dispensing pembrolizumab, nivolumab, and denosumab within Medicare (together accounting for 73.0% of Medicare revenue).

Medicare: Complete Services Breakdown

The CPT/HCPCS codes generating the most Medicare revenue for this provider.

64 rows

CPT/HCPCS Code	Description	Claims	Avg Paid	Revenue
J9271	Injection, pembrolizumab, 1 mg	36,200	$40	$1.6M
J9299	Injection, nivolumab, 1 mg	51,650	$20	$1.2M
J0897	Injection, denosumab, 1 mg	31,980	$20	$575.6K
J1569	Injection, immune globulin, (gammagard liquid), non-lyophilized, (e.g., liquid), 500 mg	6,640	$40	$238.9K
Q5126	Injection, bevacizumab-maly, biosimilar, (alymsys), 10 mg	2,650	$60	$145.7K
99214	The provider sees an established patient for an office visit or other outpatient visit involving evaluation and management. The visit involves a moderate level of medical decision making, and/or the…	1,450	$100	$138.7K
J1437	Injection, ferric derisomaltose, 10 mg	7,100	$20	$113.6K
J1449	Injection, eflapegrastim-xnst, 0.1 mg	4,220	$30	$109.8K
96413	Chemotherapy is a therapeutic procedure used for the treatment of cancer via the use of chemical agents. These chemical agents (drugs) work on the cancerous cells of the body to destroy them. These…	910	$100	$88K
J0885	Injection, epoetin alfa, (for non-esrd use), 1000 units	9,800	$10	$58.8K

Showing 1–10 of 64

Medicare: Competitive Analysis & Benchmarks

How this provider's Medicare billing volume and revenue compare to other providers nationally and within its state, across 64 CPT/HCPCS codes.

View: State1 / 2

Claims Volume vs. Florida Distribution

Vijay Patel — 11 of 25 codes billed far more than typical (above p95)

p5–p95 (all providers)p25–p75MedianThis providerOutlier

Rank Distribution — Florida

Full comparison — all codes billed, vs. state median

64 rows

CPT/HCPCS Code	Rank	Provider Count	Median Claims	Avg Paid	Average Revenue
J9271	14	210	16,100	$40	$802.7K
J9299	1	70	15,580	$20	$423.9K
Q5126	3	10	3,660	$60	$189.9K
J1569	38	130	4,080	$40	$176.2K
J0897	11	1,060	3,290	$20	$106.5K
J1449	15	40	3,560	$30	$99.2K
J1437	11	110	2,700	$20	$59.9K
J0885	69	240	6,630	$10	$45.6K
J1439	48	100	24,750	$1	$29.5K
96413	19	730	200	$100	$26.1K

Showing 1–10 of 64

Related Providers

Other providers that share a Tax Identification Number (TIN) with Vijay Patel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
Florida Cancer Specialists & Research Institute, LLC	FL	Medical Oncology Physician	$0	$63.5M
Wilfredo Blasini	FL	Clinical Pathology Physician	$16.9M	$307.9K
Ryan Olson	FL	Anatomic Pathology & Clinical Pathology Physician	$12.8M	$80
Robert Mcdonald	AZ	Diagnostic Radiology Physician	$7.5M	$0
Christopher Lobo	FL	Medical Oncology Physician	$6.1M	$0
Syed Zafar	FL	Medical Oncology Physician	$6M	$0
Ronald Goodwich	FL	Nuclear Medicine Physician	$5.7M	$0
Steven Newman	FL	Medical Oncology Physician	$5.7M	$0
Andrew Lipman	FL	Medical Oncology Physician	$5.6M	$0
Jay Wang	FL	Medical Oncology Physician	$4.5M	$0

Nearby Providers

Other providers in the same ZIP code as Vijay Patel, ranked by combined Medicare and Medicaid revenue.

Provider	State	Taxonomy	Medicare Revenue	Medicaid Revenue
North Florida Regional Medical Center, Inc.	FL	General Acute Care Hospital	$0	$21.8M
Andres Bhatia	FL	Medical Oncology Physician	$2.3M	$0
Cardiac And Vascular Institute Ambulatory Surgery Center, LLC	FL	Ambulatory Surgical Clinic/Center	$2.1M	$0
Laser And Outpatient Surgery Center LLC	FL	Ambulatory Surgical Clinic/Center	$1.3M	$3.7K
North Florida Gi Center Ltd	FL	Ambulatory Surgical Clinic/Center	$1.1M	$400
Nausheen Khuddus	FL	Ophthalmology Physician	$104.5K	$692.5K
Robert Mames	FL	Ophthalmology Physician	$699.2K	$0
North Florida Regional Freestanding Surgery Center LP	FL	Ambulatory Surgical Clinic/Center	$654.1K	$0
Natrajan Subramanian	FL	Clinical Cardiac Electrophysiology Physician	$647.9K	$0
Daniel Vanroy	FL	Cardiovascular Disease Physician	$641K	$0

Vijay Patel — Billing Profile & Reimbursement Data

Sign up for Vijay Patel — Billing Profile & Reimbursement Data policy alerts

Vijay Patel — Billing Profile & Reimbursement Data

Sign up for Vijay Patel — Billing Profile & Reimbursement Data policy alerts

Key Findings

Medicare: Total Revenue Breakdown by CPT/HCPCS Code

Medicare: Complete Services Breakdown

Medicare: Competitive Analysis & Benchmarks

Related Providers

Nearby Providers

Frequently Asked Questions

References